Hyaluronidase-facilitated high-dose subcutaneous igg effectively controls parvovirus b19 infection in a pediatric cardiac transplant patient with severe t-cell lymphopenia

Rachel J. Cruz, Joseph F. Dasso, Carla Duff, Diane Krasnopero, Zsofia Long, Maryssa Ellison, Daime Nieves, Panida Sriaroon, Alfred Asante-Korang, Jolan E. Walter

Research output: Contribution to journalArticlepeer-review

Abstract

We treated three pediatric cardiac transplant patients with chronic parvovirus viremia with high-dose intravenous immunoglobulin (HD-IVIG). One patient with severe T-cell lymphopenia suffered recurrent viremia and aseptic meningitis, which resolved remarkably when he was switched to highdose hyaluronidase-facilitated subcutaneous immunoglobulin (HD-SCIG-Hy). We discuss the advantages of HD-SCIG-Hy vs HD-IVIG treatment for similar cases.

Original languageEnglish (US)
Article numberofaa076
JournalOpen Forum Infectious Diseases
Volume7
Issue number5
DOIs
StatePublished - 2020
Externally publishedYes

Keywords

  • Heart transplant
  • Immunodeficiency
  • Parvovirus B19
  • Pediatric
  • Subcutaneous immunoglobulin

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Hyaluronidase-facilitated high-dose subcutaneous igg effectively controls parvovirus b19 infection in a pediatric cardiac transplant patient with severe t-cell lymphopenia'. Together they form a unique fingerprint.

Cite this